30 closest matches · ranked by relevance
Malignant Peripheral Nerve Sheath Tumors · MPNST · Sarcoma
Primary: Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease at ≥ 4 Months Using World Health Organization (WHO) Criteria) of Everolimus in Combination…
Malignant Peripheral Nerve Sheath Tumors (MPNST) · Sarcoma
Primary: Number of Dose Limiting Toxicities of Ganetespib When Administered in Combination With Sirolimus. — 0; 1 DLTs
Malignant Peripheral Nerve Sheath Tumors · Neurofibromatosis 1
Primary: Clinical Benefit Rate of Selumetinib in Combination With Sirolimus in Patients With Unresectable or Metastatic NF1 Associated or Sporadic MPNST. — 0.095 Proportion
Neurofibromatosis Type 1 · Sarcoma
Primary: Number of Participants With Response Rate (Complete Response and Partial Response) — 5; 4; 0; 0 Participants
Sarcoma
Primary: Patients With Response (Confirmed Complete, and Partial) With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumor When Treated With Erlotinib. — 0…
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Post-Mastectomy Chronic Pain Syndrome
Primary: Change in Pain Level — 6.9; 0.6; 4.4; 2.5 score on a scale
Neurofibromatosis Type 1 and Growing or Symptomatic, Inoperable PN
Primary: Percent of Participants With a 20% or More Change in Target Tumor Volume — 0; 8; 11; 0 Participants
Neurofibromatosis
Primary: Percent Change From Baseline in Tumor Volume at 6 Months — 17 percentage change of tumor volume
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
Sarcoma · Metastases · Chemotherapy
Primary: Correlation Between Time to Next Treatment (TNT) and Overall Survival (OS) Under First-line Treatment — 0.76 correlation coefficient
NF1 · Neurofibromatosis · Plexiform Neurofibromas
Primary: The Change in Tumor Size Based on Radiographic Assessment — -15.7; -4.1 mm^3
Liposarcoma · Leiomyosarcoma · Fibrosarcoma
Primary: Number of Participants With Overall Response (OR) — 1 participants
Neurofibromatosis 1 · Neurofibroma, Plexiform
Primary: Median Time to Disease Progression — 13.2 Months
Painful Digital Neuroma
Primary: Static 2-point Discrimination Test — 7.3 mm
Sarcoma
Primary: Number of Patients With Dose Limiting Toxicities. — 0; 1; 0 Participants
Nerve Injury
Primary: Michigan Hand Questionnaire (MHQ) in TPNI Subjects Post Surgery — 33; 83; 5; 75 score on a scale
Glioma
Primary: Number of Patients Who Had 6-month Progression-free Survival. — 3 Participants
Plexiform Neurofibroma
Primary: Number of Participants With Imaging Response in Strata 1 and 2 — 0; 1; 1; 0 participants
Sarcoma
Primary: Adherence Rate to Diagnosis Imaging Guidelines for Patients With a Deep Sarcoma Tumor (Before Implementation of the Public Health Intervention Programme. — 145…
Dermatofibrosarcoma Protuberans
Primary: To Collect Matched Tumor Tissue of Trial Participants With Dermatofibrosarcoma Protuberans Before and After Treatment With Imatinib for Future Use in cDNA Microarray and…
Neurofibromatosis Type 1
Primary: Time to Disease Progression Based on Volumetric MRI — 15.4 Months
Neurofibromatosis Type 1 · Precancerous Condition
Primary: Time to Disease Progression — 25.8; 29.2; 25.8 Months
Neurofibromatosis · NF1 · Neurofibromas
Primary: Disease Response — 0; 0; 2; 1 Participants
Diabetic Peripheral Neuropathy
Primary: Measurement of b-FGF, v-EGF MEASURED BY ELISA — 30.2; 55.4; 30.3; 428.7 pg/ml — p=0.005
Sarcoma
Primary: Number of Participants With Engraftment — 23 Participants
Neurofibromatosis · Neurofibromas
Primary: Disease Response — 13; 0; 0; 0 Participants
Advanced and / or Metastatic Liposarcoma
Primary: Progression-free Survival (PFS) Assessed 12 Weeks After Start of Treatment — 54.1; 46.2 percentage of participants
Metastatic Bone Tumor
Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months
Cutaneous Neurofibroma · Neurofibromatosis Type 1 · Optic Nerve Glioma
Primary: Median Best Response of Cutaneous Neurofibromas in Participants With at Least One Restaging Evaluation — -28.5 percent change